SC-101 / ConjuStar - LARVOL DELTA

SC-101, a Nectin-4-targeting peptide-drug conjugate (PDC), in patients (pts) with advanced or metastatic solid tumors: Results from dose escalation study (ESMO 2025) - P1 | "Conclusions SC-101 was well-tolerated with promising preliminary anti-tumor efficacy in pts with heavily pretreated solid tumors. The dose expansion study in UC, ESCC, head and neck squamous cell cancer (HNSCC), TNBC, and other solid tumors is ongoing."

Clinical • Metastases • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • Urothelial Cancer • NECTIN4

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Tianjin ConjuStar Biologics Co., Ltd.

New P2 trial • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Study SC-101 in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Tianjin ConjuStar Biologics Co., Ltd. | Trial completion date: Dec 2025 ➔ Sep 2026 | Trial primary completion date: Jun 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Xinglian Peptide recently completed a RMB 100 million Pre-A+ round of financing, and two products entered the clinical trial stage [Google translation] (vbdata.cn) - "Recently, Tianjin Xinglian Peptide Biotechnology Co., Ltd...announced the completion of a RMB 100 million Pre-A+ round of financing. This round of financing was led by Fosun Pharma's Fujian Capital New Drug Innovation Fund, and followed by Hengqin Venture Capital and Shenzhen Qianhai Liyuan. This round of financing will provide important financial support for Xinglian Peptide's product research and development, to promote clinical trials of core products and new product development, and accelerate the clinical transformation of innovative XDC drugs."

Financing • Oncology

Study SC-101 in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Tianjin ConjuStar Biologics Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Study SC-101 in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Tianjin ConjuStar Biologics Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor